With so many patients relying on novel therapeutics for neurological disorders, the stakes are high when therapies reach the clinic. The best way to improve your chance for success is to design rigorous preclinical studies that include reproducible endpoints and robust biomarkers that predict clinical efficacy. Charles River hopes you join us as we further […]
Spotlight Q&A with Rob Neville, CEO, Savara Pharmaceuticals
/ big4bio
About Savara Pharmaceuticals: Savara Inc. (NASDAQ: SVRA) is an orphan lung disease company. Savara’s pipeline comprises a number of late stage therapeutics each targeting difficult to treat lung diseases. For people not familiar with Savara, can you provide a brief overview and focus? Neville: Savara was founded in 2008 and based in Austin, Texas. Our […]